VIRATECH’S DIABETES BOOK NO. 1 AMAZON BEST SELLER

Photo of author

STOCKTON, CALIFORNIA/March 5, 2013/ Newswire/ — Viratech Corp. (OTC: VIRA), the first open source biotech research social network platform, announced today that its e-book publication of “Reversing Diabetes” on Amazon’s Kindle platform, by Dr. Barkat Charania and Dr. Kevin Buckman, is the number one best seller in alternative medicine and number one in diabetes.  The book can be purchased here: http://www.amazon.com/dp/B00BLTJAS2.

The book discusses in detail Artificial Pancreas Therapy, the only proven therapy that has been found to treat and reverse many of the complications of diabetes, as well as other methods of treatment.

“Diabetes is now a worldwide problem and one of the most expensive medical problems, costing over $150 billion a year in the US,” states Dr. Buckman. “We are working to find new solutions for diabetes, and information in this new book allows people who are afflicted with the disease can have access to the vital information that it provides. It also coincides with Viratech’s agreement to develop a social network for the Diabetes.net website. This same platform is being used for cancer and we plan to market this for various diseases and for use by nonprofits, businesses, and foundations,” he added.

About Viratech Corp.

Viratech Corp. has created the first open source biotech research social network platform. The purpose of the platform is to make it possible for individuals or smaller companies to compete with larger companies in the race to patent new medicines or technology. This has been made possible by leveraging social collaboration in a way that allows new biotech ventures the ability to protect their intellectual property, then simultaneously allowing those same ventures the ability to promote and crowdsource their development.

Forward-Looking Statements:

This press release includes forward-looking statements concerning the future performance of our business, its operations and its financial performance and condition, and also includes selected operating results presented without the context of accompanying financial results. These forward-looking statements include, among others, statements with respect to our objectives and strategies to achieve those objectives, as well as statements with respect to our beliefs, plans, expectations, anticipations, estimates or intentions. These forward-looking statements are based on our current expectations. We caution that all forward-looking information is inherently uncertain and actual results may differ materially from the assumptions, estimates or expectations reflected or contained in the forward-looking information, and that actual future performance will be affected by a number of factors, including economic conditions, technological change, regulatory change and competitive factors, many of which are beyond our control. Therefore, future events and results may vary significantly from what we currently foresee. We are under no obligation (and we expressly disclaim any such obligation) to update or alter the forward-looking statements whether as a result of new information, future events or otherwise.

 

Contact: Kevin Buckman MD

Viratech, Corp.

http://viratech.org

Email Contact: info@viratech.org

209-477-3030